Jeito Capital

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€1,000m

Latest public closing

31 Mar 2026

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

Independent private equity investor focused on biopharma, supporting companies developing innovative medicines.

Focus: Clinical-stage biopharma with serious unmet medical needs, including oncology, autoimmune and inflammatory diseases, ophthalmology, cardiology, obesity and women's health

8 April 2026: Jeito II reached final close above €1bn (also reported as $1.2bn), with final closing on 31 March 2026 (company press release).